S4 Medical Corp., a Columbus-based medical device company focused on protecting the esophagus from thermal damage during catheter ablation procedures, has completed an oversubscribed round of funding following its successful human study.
Investors include Ohio Innovation Fund, ProMedica, Plug and Play, Valley Growth Ventures, Jumpstart, North Coast Angel Fund and individual angel investors.
“This is yet another groundbreaking technology coming out of The Ohio State University, Wexner Medical Center," OIF Managing Director and S4 Board Member Bill Baumel said, in a statement. “With S4’s leadership team, comprised of one of the top electrophysiologists in the country and a seasoned medtech executive, combined with an acute need and elegant solution, S4 is positioned to be wildly successful by protecting patients from major esophageal damage during cardiac ablation.”
S4 Medical completed its first human studies in seven patients in Argentina. The company is co-invented and co-founded by Dr. Emile Daoud, chief of Cardiac Electrophysiology at The Ohio State University Wexner Medical Center.
“With the successful outcomes from our recent studies, we are pleased to have an oversubscribed round," S4 Co-founder and CEO William Fuller stated. “This new funding keeps us on the fast pace we have experienced to date and will take us through new milestones proving the value of the technology.”
